QCLS

distress 6/10 · elevated risk

$3.36+2%today-78% from 52w high

qctechnologies.com3 employeesFounded 2014New York, NYComputer Hardware

Revenue

pre-revenue

Liquidity

$14M

Runway

1.5 yrs

Shares 1y

-96%

Price & events

-17.4% over 6M

CatalystRating changeDilutionFinancingdashed = today

+1.5%

+1.8%

-13.6%

-9.2%

-40.7%

-70.0%

-98.2%

-100.0%

All

Overview

Market Cap: $26.39M
Volume: 23.46K
52 Week Range: $2.75 – $15.40
Total Shares: 7.85M
Float Shares: 7.78M
Short %: 105.11%
% Held by Insiders: 7.85%
% Held by Institutions: 7.99%
RVOL: 0.10x
Beta: 2.14

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 2

2025-12-08partnershipEntered consulting agreement with Ocean Avenue Holdings LLC for advisory services.SEC 8-K
2025-09-02partnershipEntered into Securities Purchase Agreement for private placement of Series H preferred stock and warrants.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 7,853,429 · 1 offerings/1y · 3 PIPEs

2026-02-17EFFECTshelf_effective
2026-02-11S-3shelf_registration
2026-01-238-Kmaterial_agreement
2025-12-098-Kprivate_placement
2025-12-01424B3offering
2025-11-28EFFECTshelf_effective
2025-10-038-Kprivate_placement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified